Izba (travoprost)
- Region
- 🇪🇺 EU
- Active substance
- travoprost
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Ocular Hypertension; Glaucoma, Open-Angle
- EU approval
- Thu 20 Feb 2014
- Application
- EMEA/H/C/002738
- ATC
- S01EE04
- Official record
- www.ema.europa.eu
Indication
Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 DuoTrav Authorised · Novartis Europharm Limited
- 🇪🇺 Travatan Authorised · Novartis Europharm Limited
Follow Izba
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.